CIPLA Share Price, Analysis & Fundamentals

Cipla shares gained amid a pharma rally, supported by Nomura's Buy rating and Q1 margin recovery expectations despite recent profit declines.

The market exhibits a bullish trend with prices above short-term EMAs, but valuation metrics suggest potential overvaluation.
The company's revenue, net profit, and EPS have declined both quarter-over-quarter and year-over-year.
Analysts maintain a positive outlook with 60% Buy/Strong Buy ratings, and the distribution has been stable.
Institutional investors hold a significant stake, with a recent shift from FIIs to DIIs.
Recent events include a USFDA inspection with one observation and the issuance of a SEBI compliance certificate.
News highlights include a 3% jump in Cipla shares amid a pharma rally, with Nomura retaining a Buy rating and expecting Q1 margin recovery.

The market shows a bullish trend alignment with a score of 3.
The current price is above the 9-day and 21-day EMAs, indicating short-term upward momentum.
The RSI is at 55.68, suggesting neutral momentum, while the RSI percentile over the past year is high at 70.69, indicating strong past performance.
The P/E ratio is at 33.8, which is significantly higher than the 6-month average of 26.359 and is in the 94.444th percentile over the last 6 months, suggesting the stock may be overvalued.
The P/B ratio is 3.4, slightly above the 6-month average of 3.279 and in the 86.508th percentile, indicating a premium valuation.

The market is exhibiting a bullish trend alignment, with the current price trading above key short-term moving averages (9-day and 21-day EMAs). While the RSI is in neutral territory, its high percentile over the past year suggests strong historical performance. However, valuation metrics indicate potential overvaluation, with both P/E and P/B ratios trading significantly above their 6-month averages and at high percentiles. This suggests a divergence between the bullish technical signals and stretched valuation, which could pose a risk if the market sentiment shifts.

Revenue for Mar 2026 quarter was ₹6,541 Cr.
Net profit saw a QoQ decrease of -19.436% and a YoY decrease of -55.272%.
EPS experienced a QoQ decline of -17.921% and a YoY decline of -54.594%.
Profit before tax decreased by -20.829% QoQ and -52.992% YoY.

Invagen's manufacturing facility in New York received one Form 483 observation following a USFDA inspection. Additionally, a certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 was issued.